Stock market highlights from after-hours trading, featuring Klaviyo's strong earnings results, IMAX's disappointing performance, BioMarin Pharmaceutical's positive growth, and updates on Carvana, Tanger, and Palantir.
Check out the companies making headlines in after-hours trading: Klaviyo — The software company surged almost 6% after fourth-quarter results topped Wall Street expectations. Klaviyo posted adjusted earnings of 7 cents per share on $270 million in revenue, above the 6 cents per share and $257 million in revenue that analysts surveyed by LSEG were estimating.
IMAX — The large screen, high-resolution and surround sound movie company slid nearly 5% following weaker-than-expected fourth-quarter earnings and revenue. IMAX earned 27 cents per share on $93 million in revenue in the latest quarter, below the consensus estimate of 28 cents per share and $103 million in revenue, according to LSEG. BioMarin Pharmaceutical — Shares gained more than 7% on the heels of stronger-than-expected fourth-quarter earnings, when BioMarin earned 64 cents per share on $747 million in revenue, while analysts polled by FactSet had penciled in 53 cents per share on $712 million in revenue. Carvana — The online marketplace for used cars slid nearly 12%. Gross profit per unit for retail sales came in at $6,671 in the fourth quarter, falling short of FactSet consensus estimates of $6,851. Fourth-quarter earnings of 56 cents per share and revenue of $3.55 billion topped Street estimates, however. Tanger — The outlet mall operator rose more than 2% after topping the Street's expectations for the fourth quarter. Tanger earned 23 cents per share on revenue of $141 million, above the 20 cents per share on $129 million in revenue that analysts were expecting, per LSEG. The company also forecast better-than-expected earnings for the full year. Palantir — The defense contractor fell another 1% after tumbling 1% Wednesday after its chief executive, Alex Karp, adopted a new stock trading plan . The Washington Post also reported that the Pentagon has been ordered to prepare plans to cut the U.S. defense budget by 8% annually over the next five years. — CNBC's Darla Mercado contributed reporting.
Earnings Technology Retail Defense Market
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Christopher Nolan's The Odyssey: An Epic Journey to IMAXChristopher Nolan's upcoming adaptation of Homer's The Odyssey promises to be a cinematic spectacle. The film boasts an all-star cast and will be shot using cutting-edge IMAX technology.
Read more »
The Final Destination 6 Reaches Musical Score Milestone, IMAX Plans, and MoreThe sixth installment of the Final Destination franchise is nearing completion, with composer Tim Wynn confirming the musical score is finished and directorial duo Zach Lipovsky and Adam Stein bringing a fresh perspective to the series. With an unprecedented worldwide IMAX release planned, the film promises to honor its legacy while pushing the franchise in bold new directions. The May 2025 release date remains on track, despite pandemic-related delays and the 2023 Hollywood labor strikes.
Read more »
Parasite to Return to Cinemas with IMAX ReleaseBong Joon-ho's acclaimed film Parasite, the first non-English language film to win Best Picture at the Academy Awards, will be re-released in cinemas starting February 7th with an exclusive IMAX run.
Read more »
Parasite to Return to Cinemas in Exclusive IMAX ReleaseBong Joon-ho's Oscar-winning film Parasite is getting a special re-release in IMAX theaters starting February 7th. The critically acclaimed film, which explores class inequality and social commentary through a darkly comedic lens, will be a must-see for fans and newcomers alike.
Read more »
Parasite to Hit IMAX Theaters NationwideNEON celebrates the Oscar win of the acclaimed film 'Parasite' by bringing it to IMAX theaters nationwide.
Read more »
Klaviyo Soars, IMAX Drops in Extended TradingKlaviyo stock surged almost 6% after exceeding fourth-quarter earnings and revenue expectations. IMAX, on the other hand, fell nearly 5% due to weaker-than-expected results. BioMarin Pharmaceutical also saw its shares climb over 7% on strong fourth-quarter performance.
Read more »